A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity
A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity
批准号:
10927087
负责人:
RANIER NG
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2027-07-31
关键词:
AddressAntibodiesBindingBiological AssayContractsDevelopmentDiagnosticGoalsHIV InfectionsHIV-1Human immunodeficiency virus testImmunoassayInfectionLaboratoriesMolecularNucleic AcidsReverse TranscriptionSamplingSensitivity and SpecificitySerologyTestingVaccinesclinical practicediagnostic platformnext generationnovel diagnosticspoint of careprogramsself testingseropositive
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a novel diagnostic platform that automates a HIV-1 qualitative reverse transcription PCR (RT-PCR) test together with two direct antibody binding assays to differentiate HIV-1 infection from VISP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金